NASDAQ:FLGT - Nasdaq - US3596641098 - Common Stock - Currency: USD
NASDAQ:FLGT (6/3/2025, 2:40:55 PM)
21.32
+0.65 (+3.14%)
The current stock price of FLGT is 21.32 USD. In the past month the price increased by 0.63%. In the past year, price increased by 1.82%.
Symbol | Company Name | TA | FA | PE | Market Cap |
---|---|---|---|---|---|
CI | THE CIGNA GROUP | 11.27 | 83.14B | ||
CVS | CVS HEALTH CORP | 10.01 | 80.52B | ||
LH | LABCORP HOLDINGS INC | 16.98 | 20.94B | ||
DGX | QUEST DIAGNOSTICS INC | 18.89 | 19.38B | ||
FMS | FRESENIUS MEDICAL CARE-ADR | 15.31 | 16.71B | ||
BTSGU | BRIGHTSPRING HEALTH SERV - BTSG 6 3/4 02/01/27 | 134.92 | 14.58B | ||
HIMS | HIMS & HERS HEALTH INC | 80.09 | 12.37B | ||
DVA | DAVITA INC | 14.57 | 10.17B | ||
CHE | CHEMED CORP | 24.18 | 8.34B | ||
CRVL | CORVEL CORP | 31.41 | 5.76B | ||
GH | GUARDANT HEALTH INC | N/A | 5.72B | ||
OPCH | OPTION CARE HEALTH INC | 25.4 | 5.16B |
Fulgent Genetics, Inc. is a technology company, which engages in the provision of gene testing and sequencing solutions. The company is headquartered in El Monte, California and currently employs 1,313 full-time employees. The company went IPO on 2016-09-28. Its laboratory services business includes technical laboratory and testing services and professional interpretation of laboratory results by licensed physicians. Its therapeutic development business is focused on developing drug candidates for treating a range of cancers using a novel nanoencapsulation and targeted therapy platform designed to improve the therapeutic window and pharmacokinetic profile of new and existing cancer drugs. Its testing services include comprehensive anatomic pathology testing services, including gastrointestinal pathology, dermatopathology, urologic pathology, breast pathology, neuropathology, and hematopathology, and precision diagnostics testing services, including next-generation sequencing (NGS), tests for biopharma research and clinical tests for rare disease, hereditary cancer, reproductive health, and many other diseases.
FULGENT GENETICS INC
4399 Santa Anita Ave
El Monte CALIFORNIA 91780 US
CEO: Ming Hsieh
Employees: 1313
Phone: 16263500537
The current stock price of FLGT is 21.32 USD. The price increased by 3.14% in the last trading session.
The exchange symbol of FULGENT GENETICS INC is FLGT and it is listed on the Nasdaq exchange.
FLGT stock is listed on the Nasdaq exchange.
9 analysts have analysed FLGT and the average price target is 23.12 USD. This implies a price increase of 8.44% is expected in the next year compared to the current price of 21.32. Check the FULGENT GENETICS INC stock analysts ratings, price target forecast and up-and down grades for more detailed information.
FULGENT GENETICS INC (FLGT) has a market capitalization of 648.98M USD. This makes FLGT a Small Cap stock.
FULGENT GENETICS INC (FLGT) currently has 1313 employees.
FULGENT GENETICS INC (FLGT) has a support level at 20.19 and a resistance level at 20.72. Check the full technical report for a detailed analysis of FLGT support and resistance levels.
The Revenue of FULGENT GENETICS INC (FLGT) is expected to grow by 9.64% in the next year. Check the estimates tab for more information on the FLGT EPS, Sales, EBIT and EBITDA future analyst estimates.
There is no straightforward answer here. It depends on your investment strategy as different types of investors will look at different aspects. In any case it is important to make an informed decision and these pages can help you forming an opinion:
FLGT does not pay a dividend.
FULGENT GENETICS INC (FLGT) will report earnings on 2025-07-31, before the market open.
The PE ratio for FULGENT GENETICS INC (FLGT) is 39.48. This is based on the reported non-GAAP earnings per share of 0.54 and the current share price of 21.32 USD. Check the full fundamental report for a full analysis of the valuation metrics for FLGT.
The outstanding short interest for FULGENT GENETICS INC (FLGT) is 8.73% of its float. Check the ownership tab for more information on the FLGT short interest.
ChartMill assigns a technical rating of 8 / 10 to FLGT. When comparing the yearly performance of all stocks, FLGT turns out to be only a medium performer in the overall market: it outperformed 69.49% of all stocks.
ChartMill assigns a fundamental rating of 4 / 10 to FLGT. FLGT scores quite bad on profitability, while its financial health is fine. Not spectacular, but in line with the averages.
Over the last trailing twelve months FLGT reported a non-GAAP Earnings per Share(EPS) of 0.54. The EPS increased by 370% compared to the year before.
Industry Rank | Sector Rank | ||
---|---|---|---|
PM (TTM) | N/A | ||
ROA | -3.38% | ||
ROE | -3.62% | ||
Debt/Equity | 0 |
ChartMill assigns a Buy % Consensus number of 78% to FLGT. The Buy consensus is the average rating of analysts ratings from 9 analysts.
For the next year, analysts expect an EPS growth of -217.26% and a revenue growth 9.64% for FLGT